BCIQ Profiles

Company Profile Report

Kite reports patient death in expansion cohort of ZUMA-1 trial

Kite Pharma Inc. (NASDAQ:KITE) said a patient died from treatment-related cerebral edema in an expansion cohort of the Phase I/II ZUMA-1 trial evaluating single IV infusions of axicabtagene ciloleucel (KTE-C19) to treat chemorefractory aggressive B cell non-Hodgkin's lymphoma (NHL). The patient had developed grade 3

Read the full 459 word article

How to gain access

Continue reading with a
two-week free trial.